Tema Etfs LLC Boosts Stock Position in Amgen Inc. $AMGN

Tema Etfs LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 38.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,964 shares of the medical research company’s stock after buying an additional 4,987 shares during the period. Tema Etfs LLC’s holdings in Amgen were worth $5,069,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of AMGN. OLD National Bancorp IN raised its holdings in Amgen by 296.2% during the second quarter. OLD National Bancorp IN now owns 18,004 shares of the medical research company’s stock worth $5,027,000 after purchasing an additional 13,460 shares during the last quarter. Atlantic Union Bankshares Corp increased its position in shares of Amgen by 165.0% in the second quarter. Atlantic Union Bankshares Corp now owns 10,643 shares of the medical research company’s stock valued at $2,972,000 after buying an additional 6,627 shares in the last quarter. D.A. Davidson & CO. raised its stake in shares of Amgen by 2.6% during the 3rd quarter. D.A. Davidson & CO. now owns 243,054 shares of the medical research company’s stock worth $68,590,000 after buying an additional 6,222 shares during the last quarter. Davis Capital Management purchased a new stake in shares of Amgen in the 3rd quarter worth about $1,841,000. Finally, L2 Asset Management LLC grew its stake in Amgen by 50.8% in the 2nd quarter. L2 Asset Management LLC now owns 9,837 shares of the medical research company’s stock valued at $2,747,000 after acquiring an additional 3,314 shares during the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 10,908 shares of company stock valued at $3,674,966. Company insiders own 0.69% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: UBS upgraded Amgen (AMGN) to a “strong-buy,” a direct bullish analyst signal that can support the stock. UBS upgrade: Amgen to strong-buy
• Positive Sentiment: Amgen struck an exclusive deal with Disco/Disco Pharma tied to a cancer target (deal worth up to $618M), which strengthens Amgen’s oncology pipeline and future revenue optionality. Amgen Disco oncology pact
• Positive Sentiment: Amgen completed a Phase 1b blinatumomab study in Japan, advancing its leukemia strategy — a clinical progress update that can de-risk a program and support long-term value. Blinatumomab study completed in Japan
• Neutral Sentiment: Truist nudged Amgen’s price target slightly higher (from $318 to $319) but kept a “hold” rating — a mild signal that doesn’t materially change sell-side sentiment. Truist raises AMGN price target to $319
• Neutral Sentiment: Citi reiterated a “hold” on Amgen, indicating continued analyst caution despite pipeline wins. Citi sticks to hold for Amgen
• Neutral Sentiment: Market/sector context: Amgen is tracking with the Nasdaq life-sciences segment and will be in focus at the JPMorgan Healthcare Conference, where peers typically reveal pipeline updates and M&A intent — a neutral-to-positive thematic tailwind depending on conference takeaways. AMGN aligns with Nasdaq life sciences
• Neutral Sentiment: Sector preview: CNBC notes JPMorgan Healthcare will drive pipeline/M&A headlines across big pharmas — Amgen may benefit if it announces high-impact deals. What to expect from pharma at JPM
• Negative Sentiment: Despite the positive deal and clinical updates, shares fell amid a broader market uptick and profit-taking; a Zacks note highlighted recent intraday weakness, reflecting short-term selling pressure. Amgen stock falls amid market uptick

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on AMGN shares. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Citigroup raised their price objective on shares of Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 24th. The Goldman Sachs Group restated a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. Scotiabank initiated coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. Finally, Daiwa Capital Markets boosted their price target on Amgen from $310.00 to $370.00 and gave the stock an “outperform” rating in a report on Tuesday, November 18th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $338.55.

Amgen Price Performance

Amgen stock opened at $326.10 on Monday. Amgen Inc. has a 1 year low of $260.55 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28. The firm has a 50 day moving average price of $329.75 and a 200 day moving average price of $304.66. The company has a market cap of $175.60 billion, a price-to-earnings ratio of 25.20, a PEG ratio of 2.97 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the firm posted $5.58 earnings per share. Amgen’s revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Sell-side analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a yield of 3.1%. Amgen’s payout ratio is 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.